Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 7/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 4/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.77 |
| ▸ | LMNA | P02545 | 4/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.77 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.77 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.77 |
| ▸ | THPO | P40225 | 1/20 | 0.77 |
| ▸ | MTOR | P42345 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aldosterone SCHEMBL15935548 | 1.00 | NR3C2 (1.00) | NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2 | |
| Aldosterone SCHEMBL19327156 | 1.00 | NR3C2 (1.00) | NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2 | |
| Aldosterone SCHEMBL7191919 | 1.00 | NR3C2 (1.00) | NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2 | |
| Aldosterone SCHEMBL21950215 | 1.00 | NR3C2 (1.00) | NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2 | |
| Aldosterone SCHEMBL1675 | 1.00 | NR3C2 (1.00) | NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2 | |
| Aldosterone SCHEMBL14373307 | 1.00 | NR3C2 (1.00) | NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2 | |
| Aldosterone SCHEMBL21267959 | 0.99 | NR3C2 (0.98) | NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2 | |
| Aldosterone SCHEMBL21082811 | 0.99 | NR3C2 (0.98) | NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2 | |
| Aldosterone SCHEMBL27949081 | 0.99 | NR3C2 (0.98) | NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2 | |
| Aldosterone SCHEMBL7992710 | 0.97 | NR3C2 (0.94) | NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | claimed |
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | Illudent, Inc. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-12269793-B2 | Affinity illudofulvene conjugates | AF CHEMICALS, LLC (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4257186-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4257186-A2 | AFFINITY MEDICANT CONJUGATES | AF Chemicals LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230263829-A1 | ENABLING CHOLESTEROL CATABOLISM IN HUMAN CELLS | University of South Alabama Foundation for Research and Commercialization | 2023-08-24 | — | — | US | disclosed |
| EP-3129357-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20040138187-A1 | Therapeutic treatment methods | BIOVIE INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004019953-A1 | THERAPEUTIC TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1372664-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030083231-A1 | Blood cell deficiency treatment method | BIOVIE INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2002069977-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| US-6197833-B1 | Neuroprotective effects of polycyclic phenolic compounds | APOLLO BIOPHARMACEUTICS, INC. | 2001-03-06 | — | — | US | disclosed |
| US-5859001-A | Neuroprotective effects of polycyclic phenolic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0565674-B1 | METHOD FOR MEMORY ENHANCEMENT AND QUALITY OF LIFE IMPROVEMENT | HOPE CITY (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | NR3C2 3284/4885SHBG 366/4885SERPINA6 299/4885 |
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | NR3C2 606/4885SHBG 27/4885SERPINA6 79/4885 |
| US-20030083231-A1 | Blood cell deficiency treatment method | THPO, HPGDS, MPL | NR3C2 54/4885SHBG 26/4885SERPINA6 362/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | NR3C2 606/4885SHBG 27/4885SERPINA6 79/4885 |
| US-12269793-B2 | Affinity illudofulvene conjugates | OGFR, TNFSF11, FCER2 | NR3C2 3284/4885SHBG 366/4885SERPINA6 299/4885 |
| US-20040138187-A1 | Therapeutic treatment methods | ELANE, ALOX15, IL15 | NR3C2 30/4885SHBG 93/4885SERPINA6 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.